II. Epidemiology
- Renal Artery Stenosis is the most common cause of Secondary Hypertension (1-5%)
- Responsible for as much as 25% of Hypertension refractory to medications
- Responsible for 10-25% of Severe Hypertension or Malignant Hypertension in white patients
III. Types
- Atherosclerotic Renal Artery Stenosis (90%)
- Most common cause of Renal Artery Stenosis in age over 65 years old
- Associated with comorbid Coronary Artery Disease and Peripheral Arterial Disease
- Fibromuscular Dysplasia (10%): Also associated with ruptured aneurysms and dissections
- Most common cause of Renal Artery Stenosis in age under 40 years old (especially women)
- Sub-types
- Medial fibroplasia (most common FMD type, has string of beads appearance on imaging)
- Perimedial fibroplasia
- Intimal fibroplasia
- Adventitial fibroplasia
IV. Evaluation: Diagnostic Clues
-
Hypertension
- Recent onset of Hypertension
- Isolated Hypertension is associated with Renal Artery Stenosis in 5% of cases
- Up to 40% of those with Hypertension and atherosclerotic disease have Renal Artery Stenosis
- Gupta (2017) Curr Cardiol Rep 19(9): 75 [PubMed]
- No Family History of Hypertension
- Hypertension onset under age 30 or over 55 years
- Hypertension with Hypokalemia and Hyponatremia (Hyperaldosterone state)
-
Hypertension resistant to therapy
- Increased Blood Pressure on Diuretic
- Excellent response to ACE Inhibitor
- ACE Inhibitor increases Serum Creatinine 50% or more over baseline
- Recent onset of Hypertension
- Comorbid vascular disease
- Retinopathy
- Systolic or diastolic abdominal bruit
- Long History of Tobacco use
- Coronary Artery Disease
- Cerebrovascular Disease
- Peripheral Vascular Disease
- Renal dysfunction
- Especially Serum Creatinine rise 50% or more over baseline within one week of starting ACE Inhibitors (or ARBs)
- Serum Creatinine increase suggests bilateral Renal Artery Stenosis
- Recurrent Pulmonary Edema
- Asymmetric or bilaterally small Kidneys
- Especially Serum Creatinine rise 50% or more over baseline within one week of starting ACE Inhibitors (or ARBs)
V. Labs: Diagnosis (rarely used - imaging is gold standard)
- Plasma renin assay before and after ACE Inhibitor
- Morning Sample
- Unusual to be <3ng/ml/hour in renal vascular disease
VI. Imaging: Diagnosis
- Renal artery duplex sonography (Preferred first Screening Test where experienced operators)
- Efficacy
- Test Sensitivity markedly reduced in Obesity and if significant overlying bowel gas
- Operator dependent for accurate results (requires experienced technician)
- Test Sensitivity: 75-98%
- Test Specificity: 62-99% (Better Specificity than MRA)
- Diagnostic Criteria
- Peak systolic velocity in renal artery >1.8 to 2.0 m/sec
- Renal artery to aortic velocity ratio >3.5
- Renal resistive index (RRI) has prognostic value pre-operatively
- RRI<80 predicts best Hypertension improvement with revascularization
- Efficacy
- Magnetic Resonance Angiography (MRA)
- Considered preferred Screening Test if sonographer not experienced with RAS screening
- Precaution: Gadolinium-Induced Nephrogenic Systemic Fibrosis (nearly always fatal)
- Consider alternative screening in Renal Insufficiency (esp. where Serum Creatinine >2.5)
- Efficacy
- Overestimates extrarenal stenosis
- Test Sensitivity: 90-100%
- Test Specificity: 76-94%
- CT Angiography
- Precautions
- Do not use if Renal Insufficiency due to Intravenous Contrast material
- Significant radiation exposure
- Efficacy
- Test Sensitivity: 89-100%
- Test Specificity: 82-100%
- Precautions
- Radionuclide renal scan with and without ACE Inhibitor (Captopril Renography)
- Test Sensitivity: 80-100%
- Test Specificity: 90%
- Safe even in Renal Insufficiency
- However not reliable in poor Renal Function or bilateral Renal Artery Stenosis
- May help stratify those who will have greatest benefit from RAS intervention
- Arteriogram (Angiography)
- Gold standard but invasive, interobserver variability, and not used as a Screening Test
- References
VII. Management: Medical
- See Prevention of Kidney Disease Progression
- Optimal medical therapy has equivalent or better outcomes than renal artery stenting in most patients
-
Hypertension control
- ACE Inhibitor or Angiotensin Receptor Blocker
- Expect some increase in Serum Creatinine
- Stop if Serum Creatinine increases 20% in first 4 days of starting (or 30% later)
- Diuretics (e.g. Chlorthalidone or Hydrochlorothiazide)
- ACE Inhibitor or Angiotensin Receptor Blocker
-
Hyperlipidemia control (goal LDL 70-100)
- Statin AntiHyperlipidemics (e.g. Simvastatin)
- Maximize Diabetes Mellitus management
VIII. Management: Surgical interventions for revascularization
- Indications
- Refractory Hypertension on 3 or more medications including a Diuretic
- Progressive Azotemia
- Acute Renal Failure with ACE Inhibitor (or ARB) with comorbid Congestive Heart Failure
- Recurrent flash Pulmonary Edema
- Bilateral Renal Artery Stenosis
- Stenosis of solitary Kidney
- Renal resistive index <0.80
- Contraindications (Relative): Factors favoring conservative therapy
- Good Hypertension control on 1 or 2 agents
- Normal Renal Function
- Advanced renal atrophy (<7.5 cm)
- Renal resistive index >0.80 (predicts poor Hypertension response to revascularization)
- Significant Proteinuria
- Procedures
- Surgical Revascularization
- Rarely used now unless undergoing concurrent open AAA repair
- Percutaneous transluminal renal Angioplasty
- Stenting has replaced PTRA in most centers due to recoil and recurrent stenosis
- Renal artery stenting (preferred first-line test)
- Surgical Revascularization
- Efficacy
- Small study suggests outcomes from medical management is equivalent to surgical management
- Stenting confers risk (including mortality from massive Cholesterol emboli)
- Bax (2009) Ann Intern Med 150(12): 840-8 [PubMed]
- Small study suggests outcomes from medical management is equivalent to surgical management
IX. Prognosis: Five year survival in atherosclerotic Renal Artery Stenosis
- Unilateral Renal Artery Stenosis: 96% five year survival
- Bilateral Renal Artery Stenosis: 74% five year survival
- Stenosis or Occlusion of solitary Kidney: 47% five year survival
- End-stage renal disease on Hemodialysis: 18% five year survival (50% two year survival)
X. References
- Shetty (2007) 29th Annual CV Conference, HealthPartners, St. Paul, MN
- Firnhaber (2022) Am Fam Physician 105(1): 65-72 [PubMed]
- Hartman (2009) Am Fam Physician 80(3): 273-9 [PubMed]